Metabolic Syndrome Components in Patients with Pituitary Adenoma
Hormone and Metabolic Research · 01.02.2024 · 56 (02) · 118-127
DOI: 10.1055/a-2209-0538 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Hormone and Metabolic Research, erschienen am 01.02.2024. Verfasst von Jorge A Gonzalez-Almazan und 6 weiteren Autor:innen. Beteiligte Einrichtung: Research Division, General Hospital of Mexico, Ciudad de Mexico, Mexico. Hauptthemen laut MEDLINE: Pituitary Neoplasms, Metabolic Syndrome, Adenoma. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 100 Literaturangaben.
Abstract (Originalsprache)
Pituitary adenomas are benign tumors of the anterior portion of the pituitary gland (adenohypophysis), representing the 25% of all the tumor alterations. Pituitary adenomas are classified by the type of hormone secreted, cellularity, size, and structural alterations by the hormonal segregation. The diagnosis consists on the histopathological identification of cell types and the image-guided by magnetic resonance or tomography; the treatment can be both pharmacological and surgical. Metabolic Syndrome is the set of clinical conditions that increase the risk of cardiovascular diseases with an estimated prevalence of 25% worldwide. The alterations of metabolic syndrome are obesity, hypertension, dyslipidemia, insulin resistance, and diabetes mellitus type II. Pituitary adenomas and metabolic syndrome have an important relationship, hormone-secreting by pituitary adenomas affects a myriad of signaling pathways, which allows a favorable environment for the appearance of the metabolic syndrome. Moreover, patients with pituitary adenomas are shown to have an improvement in metabolic parameters after the medical/surgical treatment. The objective of this review is to explore the possible mechanisms through which PAs contributes to MetSx.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Research Division, General Hospital of Mexico, Ciudad de Mexico, Mexico.
- Functional & Stereotactic Neurosurgery Unit, General Hospital of Mexico, Ciudad de Mexico, Mexico.
- Facultad de Estudios Superiores Iztacala, Universidad Nacional Autonoma de Mexico Facultad de Estudios Superiores Iztacala, Tlalnepantla, Mexico.
- Faculty of Medicine, National Autonomous University of Mexico, Ciudad de Mexico, Mexico.
- Faculty of Health Sciences, Anahuac University Mexico - Southern Campus, Ciudad de Mexico, Mexico.
- Coordination of Neuroscience, Faculty of Psychology, University Anahuac Mexico, Huixquilucan, Mexico.
Zitieren
APA
Gonzalez-Almazan, J. A., Cortes-Contreras, A. P., Flores-Rabasa, R., Mendez-Garcia, L. A., Escobedo, G., Navarro Olvera, J. L., & Carrillo-Ruiz, J. D. (2024). Metabolic Syndrome Components in Patients with Pituitary Adenoma. Hormone and Metabolic Research, 56(02), 118-127. https://doi.org/10.1055/a-2209-0538
Vancouver
Gonzalez-Almazan JA, Cortes-Contreras AP, Flores-Rabasa R, Mendez-Garcia LA, Escobedo G, Navarro Olvera JL, et al. Metabolic Syndrome Components in Patients with Pituitary Adenoma. Hormone and Metabolic Research. 2024;56(02):118-127. doi:10.1055/a-2209-0538
BibTeX
@article{GonzalezAlmazan2024,
author = {Gonzalez-Almazan, Jorge A and Cortes-Contreras, Ana Paula and Flores-Rabasa, Regina and Mendez-Garcia, Lucia A and Escobedo, Galileo and Navarro Olvera, José L and Carrillo-Ruiz, José D},
title = {Metabolic Syndrome Components in Patients with Pituitary Adenoma},
journal = {Hormone and Metabolic Research},
year = {2024},
volume = {56},
number = {02},
pages = {118--127},
doi = {10.1055/a-2209-0538}
}
EUVIMED